Condition: Brain Arteriovenous Malformations · Sponsor: Xuanwu Hospital, Beijing
A single-center, open-label, non-randomized controlled exploratory study is conducted in the Xuanwu Hospital Capital Medical University to evaluate the efficacy and safety of FCN-159 in patients with brain arteriovenous malformations (BAVM), aiming to overcome the current clinical challenges caused by the lack of available drugs for this disease.
This description comes directly from the study's public registry record.
Tao Hong, MD · +86-13810000653 · hongtao.edu@gmail.com
Always discuss trial participation with your own doctor first.
| the Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06913725